| Abstract |
Metabolic is developing AOD-9604 for the potential treatment of obesity. By February 2002, phase IIa trials were underway. |
| Authors | John Wilding |
| Journal | Current opinion in investigational drugs (London, England : 2000)
(Curr Opin Investig Drugs)
Vol. 5
Issue 4
Pg. 436-40
(Apr 2004)
ISSN: 1472-4472 [Print] England |
| PMID | 15134286
(Publication Type: Journal Article, Review)
|
| Chemical References |
- AOD 9604
- Anti-Obesity Agents
- Peptide Fragments
- Somatostatin
|
| Topics |
- Animals
- Anti-Obesity Agents
(chemistry, pharmacology, therapeutic use)
- Clinical Trials, Phase II as Topic
- Humans
- Obesity
(drug therapy)
- Peptide Fragments
(chemistry, pharmacology, therapeutic use)
- Somatostatin
(chemistry, pharmacology, therapeutic use)
- Structure-Activity Relationship
|
